229
Views
3
CrossRef citations to date
0
Altmetric
Research Article

The Cyclin-Dependent Kinase 8 (CDK8) Inhibitor DCA Promotes a Tolerogenic Chemical Immunophenotype in CD4+ T Cells via a Novel CDK8-GATA3-FOXP3 Pathway

, , , , , , , , , , , , , , & ORCID Icon show all
Article: e00085-21 | Received 02 Mar 2021, Accepted 02 Jun 2021, Published online: 03 Mar 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Marzena Staniszewska, Kajetan Kiełbowski, Klaudia Rusińska, Estera Bakinowska, Ewa Gromowska & Andrzej Pawlik. (2023) Targeting cyclin-dependent kinases in rheumatoid arthritis and psoriasis – a review of current evidence. Expert Opinion on Therapeutic Targets 27:11, pages 1097-1113.
Read now

Articles from other publishers (2)

Xing Chen, Yaoyao Yan, Xiu Cheng, Zhaoyan Zhang, Chuanbiao He, Dan Wu, Dahai Zhao & Xinhua Liu. (2023) A novel CDK8 inhibitor with poly-substituted pyridine core: Discovery and anti-inflammatory activity evaluation in vivo. Bioorganic Chemistry 133, pages 106402.
Crossref
Tongbing Qi, Ying Luo, Weitong Cui, Yue Zhou, Xuan Ma, Dongming Wang, Xuewen Tian & Qinglu Wang. (2022) Crosstalk between the CBM complex/NF-κB and MAPK/P27 signaling pathways of regulatory T cells contributes to the tumor microenvironment. Frontiers in Cell and Developmental Biology 10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.